Get the Stockscreener App
332.42
0.08%
0.25
After Hours:
332.42
Penumbra Inc stock is traded at $332.42, with a volume of 346.41K.
It is up +0.08% in the last 24 hours and down -1.12% over the past month.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
See More
Previous Close:
$332.17
Open:
$332.19
24h Volume:
346.41K
Relative Volume:
0.35
Market Cap:
$13.05B
Revenue:
$1.40B
Net Income/Loss:
$177.69M
P/E Ratio:
73.49
EPS:
4.5234
Net Cash Flow:
$174.93M
1W Performance:
+0.40%
1M Performance:
-1.12%
6M Performance:
+31.59%
1Y Performance:
+22.10%
1-Day Range:
$332.08
$333.32
1-Week Range:
$328.86
$333.32
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
332.42 | 13.04B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance - FinancialContent
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - FinancialContent
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative? - simplywall.st
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors - AD HOC NEWS
Penumbra Presents STORM-PE 90-day Results at SIR - dicardiology.com
Study backs Penumbra computer-assisted thrombectomy - MassDevice
Penumbra (PEN) Reports Positive Outcomes from STORM-PE Trial - GuruFocus
Aug PreEarnings: What is the long term forecast for Penumbra Inc stock2026 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Penumbra trial shows improved outcomes for pulmonary embolism - Investing.com
Penumbra trial shows improved outcomes for pulmonary embolism By Investing.com - Investing.com Canada
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients - PR Newswire
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) - Yahoo Finance
Are OMEX, PEN, SNCY, CWAN Obtaining Fair Deals for their Shareholders? - Sahm
Penumbra Sale To Boston Scientific Sparks Review Of Deal Value - Yahoo Finance
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Australia
Fidelity Stock Selector Small Cap Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Investor Alert: Kahn Swick & Foti Investigates Proposed Sale - National Today
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - The AI Journal
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - FinancialContent
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & SuppliesCardiology, Neurology, Vascular Group - Yahoo Finance
Citi Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra (NYSE:PEN) Director Sells $32,822.00 in Stock - MarketBeat
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com UK
Grewal Harpreet, Penumbra director, sells $32,822 in stock By Investing.com - Investing.com South Africa
Penumbra (NYSE: PEN) director sells 100 shares under Rule 10b5-1 plan - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
JP Morgan Maintains Penumbra (PEN) Neutral Recommendation - MSN
Penumbra, Inc. (PEN) latest stock news and headlines - Yahoo Finance UK
PEN PE Ratio & Valuation, Is PEN Overvalued - Intellectia AI
Penumbra, Inc. (PEN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
SG Americas Securities LLC Has $3.46 Million Stake in Penumbra, Inc. $PEN - MarketBeat
[144] Penumbra Inc SEC Filing - Stock Titan
Boston Scientific (NYSE: BSX) to Acquire Penumbra; $374/Share Cash-or-Stock Deal - Stock Titan
Boston Scientific (NYSE: BSX) to acquire Penumbra in $374/share deal - Stock Titan
Allspring Global Investments Holdings LLC Sells 6,471 Shares of Penumbra, Inc. $PEN - MarketBeat
Are EHAB, SLAB, PEN, SKYT Obtaining Fair Deals for their Shareholders? - Sahm
Aug Macro: Is Penumbra Inc impacted by rising ratesWeekly Trade Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SLAB, PEN, SKYT, and EHAB - The Malaysian Reserve
Boston Scientific (NYSE: BSX) to Acquire Penumbra in $374/Share Deal - Stock Titan
Dow Update: What is the long term forecast for Penumbra Inc stockGlobal Markets & Verified Entry Point Detection - baoquankhu1.vn
Assessing Penumbra (PEN) Valuation As Shares Trade On A High P/E Multiple - Yahoo Finance
Vanguard disaggregates holdings; reports 0 shares in Penumbra (PEN) - Stock Titan
Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Reasons to Keep Penumbra Shares in Your Portfolio at This Time - Bitget
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):